ArticleNature medicine2011
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.
Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 88 citations in OpenAlex.
- Noncoding RNA in Clinical Trials: Diagnostic and Therapeutical Prospects.Experientia supplementum (2012) · 2026Review
- Molecular probes for in vivo optical imaging of immune cells.Nature biomedical engineering · 2025Review
- Protein and peptide engineering for chemical exchange saturation transfer imaging in the age of synthetic biology.NMR in biomedicine · 2023Review
- Dual Magnetic Particle Imaging and Akaluc Bioluminescence Imaging for Tracking Cancer Cell Metastasis.Tomography (Ann Arbor, Mich.) · 2023Article
- Manganous-manganic oxide nanoparticle as an activatable microwave-induced thermoacoustic probe for deep-located tumor specific imagingPhotoacoustics · 2022Article
- Article
- A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects.Pharmaceutics · 2022Article
- Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein.International journal of molecular sciences · 2021Review
- Synthetic biomarkers: a twenty-first century path to early cancer detection.Nature reviews. Cancer · 2021Review
- MRI detection of the malignant transformation of stem cells through reporter gene expression driven by a tumor-specific promoter.Stem cell research & therapy · 2021Article
- Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers.Scientific reports · 2021Article
- A survivin-driven, tumor-activatable minicircle system for prostate cancer theranostics.Molecular therapy oncolytics · 2021Article
- Article
- Molecular Imaging with Reporter Genes: Has Its Promise Been Delivered?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.Cancer research · 2019Article
- Article
- A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles.Gene therapy · 2019Article
- [Theranostics of osteosarcoma and lung metastasis with new integrin αZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2019Article
- Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.International journal of molecular sciences · 2019Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Molecular-genetic imaging is advancing from a valuable preclinical tool to a guide for patient management. The strategy involves pairing an imaging reporter gene with a complementary imaging agent in a system that can be used to measure gene expression or protein interaction or track gene-tagged cells in vivo. Tissue-specific promoters can be used to delineate gene expression in certain tissues, particularly when coupled with an appropriate amplification mechanism. Here we show that the progression elevated gene-3 (PEG-3) promoter, derived from a rodent gene mediating tumor progression and metastatic phenotypes, can be used to drive imaging reporters selectively to enable detection of micrometastatic disease in mouse models of human melanoma and breast cancer using bioluminescence and radionuclide-based molecular imaging techniques. Because of its strong promoter activity, tumor specificity and capacity for clinical translation, PEG-3 promoter-driven gene expression may represent a practical, new system for facilitating cancer imaging and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.